Akron Children's Hospital

The trials here

What the 33 trials at this site are about, from their registry records.

Conditions

• Epilepsy5 trials
• Stroke4 trials
• Childhood cancers3 trials
• Cystic fibrosis3 trials
• Migraine3 trials
• Lupus (SLE)2 trials
• Psoriasis2 trials
• Psoriatic arthritis2 trials
• Acute lymphoblastic leukaemia1 trial
• Bronchiectasis1 trial
• Charcot-Marie-Tooth disease1 trial
• Chronic kidney disease1 trial
• and 14 more

Phase

• Phase 311 trials
• Phase 27 trials
• Phase 42 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Completed11 trials
• Recruiting9 trials
• Active, not recruiting6 trials
• Terminated3 trials
• Not yet recruiting2 trials
• Enrolling by invitation1 trial
• Withdrawn1 trial

Lead sponsor

• Children's Hospital Medical Center, Cincinnati4 trials
• Vertex Pharmaceuticals Incorporated3 trials
• H. Lundbeck A/S2 trials
• PTC Therapeutics2 trials
• Tisento Therapeutics2 trials
• and 20 more

Running trials

• Recruiting

  Prospective Natural History Study of POLG Disease

  NCT07775872· The POLG Foundation· Source

  Contact: Bruce Bruce Cohen

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

  NCT05538208· Phase 2· Children's Hospital Medical Center, Cincinnati· Source

  Contact: Jessica Clinical Research Nurse

• Recruiting

  A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

  NCT05897320· Phase 3· H. Lundbeck A/S· Source

• Recruiting

  International Rare Brain Tumor Registry

  NCT05697874· Children's National Research Institute· Source

  Contact: Erin Wright, MD

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

  NCT05330325· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

  NCT05126758· Phase 3· Capricor Inc.· Source

• Recruiting

  A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

  NCT05164172· Phase 3· H. Lundbeck A/S· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Pfizer· Source

• Recruiting

  Epilepsy Learning Healthcare System (ELHS)

  NCT06265103· Epilepsy Foundation of America· Source

  Contact: Kelsey Merrison, MD

• Recruiting

  The Myelin Disorders Biorepository Project

  NCT03047369· Children's Hospital of Philadelphia· Source

  Contact: Matthew Ginsberg, MD

• Recruiting

  National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

  NCT02852031· Children's Hospital Medical Center, Cincinnati· Source

  Contact: Mark Timbers

• Recruiting

  Third Party Viral Specific T-cells (VSTs)

  NCT02532452· Phase 2· Children's Hospital Medical Center, Cincinnati· Source

  Contact: Courtney Culbertson, CNP

• Active, not recruiting

  HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

  NCT02875314· Phase 4· Parth Patel· Source

• Recruiting

  Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

  NCT02418442· Duke University· Source

  Contact: Jessica Kracker

• Recruiting

  Donor-Derived Viral Specific T-cells (VSTs)

  NCT02048332· Phase 1/2· Children's Hospital Medical Center, Cincinnati· Source

  Contact: Courtney Culbertson, CNP

• Recruiting

  North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

  NCT01694940· Columbia University· Source

  Contact: Bruce Cohen, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy3 recruiting
• Migraine2 recruiting
• Stroke2 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Retinitis pigmentosa1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Terminated

  An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

  NCT06961344· Phase 2· Tisento Therapeutics· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Terminated

  Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

  NCT06042257· Phase 2· Rachel G. Greenberg, MD, MB, MHS· Source

• Completed

  A Phase 2b Study of Zagociguat in Patients With MELAS

  NCT06402123· Phase 2· Tisento Therapeutics· Source

• Completed

  4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

  NCT06553547· Phase 2· Ardelyx· Source

• Completed

  Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

  NCT06506773· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

  NCT05218655· Phase 3· PTC Therapeutics· Source

• Completed

  A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

  NCT05252533· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

  NCT05001737· Phase 3· Swedish Orphan Biovitrum· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

  NCT04378075· Phase 2/3· PTC Therapeutics· Source

• Recruiting

  Two Dose Levels of Privigen in Pediatric CIDP

  NCT03684018· Phase 4· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Recruiting

  Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

  NCT04174157· Novartis Pharmaceuticals· Source

  Contact: Novartis Gene Therapies

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Incyte Corporation· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source